Canada drug agency gives final positive reimbursement recommendation for lecanemab

Eisai and Biogen said Canada’s Drug Agency (CDA-AMC) issued a final recommendation supporting public reimbursement of LEQEMBI (lecanemab) for eligible early Alzheimer’s disease patients in Canada.